Title
Authors
Francesco Chiappelli
Affiliation
Professor Emeritus, UCLA Center for the Health Sciences, Los Angeles, CA, USA
Francesco Chiappelli - E-mail: Chiappelli.research@gmail.com; *Corresponding author
Article Type
Editorial
Date
Received January 25, 2020; Accepted February 12, 2020; Published February 12, 2020
Abstract
The first report of the unusual manifestation of pneumonia-like symptoms in Wuhan City, China was made on 31 December 2019. Within one week, the Chinese authorities reported that they had identified the causative agent as a new member of the Coronavirus family, the same family of that was responsible for MERS and SARS not so many years ago. The new virus was called Novel Coronavirus 2019 (2019-nCoV). Three weeks later, the World Health Organization declared that 2019-nCoV was capable of direct human-to-human transmission, the virus had spread across several countries in three continents, and had infected close to two thousand people, of whom at least 1 in 5 quite severely. The number of fatalities was fast rising. Yet, the World Health Organization officially announced that there is still at present no recommended anti-nCoV vaccine for subject at-risk, nor treatment for patients with suspected or confirmed nCoV, let alone 2019-nCov. It is therefore timely and critical to propose new possible and practical approaches for preventive interventions for subjects at-risk, and for treatment of patients afflicted with 2019-nCov, before the present situation explodes into a world-wide pandemic. One such potential clinical protocol is proposed as a hypothesis.
Keywords
Angiotensin-converting enzyme-2 (ACE2); transcription regulatory networks (TRNs) Corona virus (CoV); Middle-East Respiratory Syndrome (MERS); Severe Acute Respiratory Syndrome (SARS); Novel Coronavirus (emerged late) 2019 (2019-nCoV)
Citation
Chiappelli, Bioinformation 16(2): 139-144 (2020)
Edited by
P Kangueane
ISSN
0973-2063
Publisher
License
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
